{Reference Type}: Journal Article
{Title}: Peroxiporins in Triple-Negative Breast Cancer: Biomarker Potential and Therapeutic Perspectives.
{Author}: Bijelić A;Silovski T;Mlinarić M;Čipak Gašparović A;
{Journal}: Int J Mol Sci
{Volume}: 25
{Issue}: 12
{Year}: 2024 Jun 17
{Factor}: 6.208
{DOI}: 10.3390/ijms25126658
{Abstract}: Triple-negative breast cancer (TNBC) remains one of the most challenging subtypes since it is initially characterized by the absence of specific biomarkers and corresponding targeted therapies. Advances in methodology, translational informatics, genomics, and proteomics have significantly contributed to the identification of therapeutic targets. The development of innovative treatments, such as antibody-drug conjugates and immune checkpoint inhibitors, alongside chemotherapy, has now become the standard of care. However, the quest for biomarkers defining therapy outcomes is still ongoing. Peroxiporins, which comprise a subgroup of aquaporins, which are membrane pores facilitating the transport of water, glycerol, and hydrogen peroxide, have emerged as potential biomarkers for therapy response. Research on peroxiporins reveals their involvement beyond traditional channeling activities, which is also reflected in their cellular localization and roles in cellular signaling pathways. This research on peroxiporins provides fresh insights into the mechanisms of therapy resistance in tumors, offering potential avenues for predicting treatment outcomes and tailoring successful TNBC therapies.